WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of

WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering in which it intends to

MORF-057 well tolerated in all dose cohorts MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 integrin at three highest dose levels; demonstrates ability to saturate α4β7 receptor Data provide early clinical proof of concept for MORF-057 as an oral, selective α4β7 inhibitor Phase 1

Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 AbbVie exercised license option to αvβ6 integrin inhibitor program for fibrotic diseases Expanded research and development collaboration with Janssen through third integrin program Conference call today at 8:00 a.m.

Call to discuss financial and operational results for fiscal year 2020 and MORF-057 interim data from SAD portion of ongoing MORF-057 Phase 1 clinical trial WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation

WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer

New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the